

Code updates

The following code is covered when prior authorized for Commercial members only:

Code	Description	Effective
S0812	Phototherapeutic keratectomy (PTK)	5/1/2020

The following code is covered for all lines of business no prior authorization is required:

Code	Description	Effective
	Infectious agent detection by nucleic acid (DNA or RNA); respiratory	1/1/2019
87634	syncytial virus, amplified probe technique	

The following services are covered for all lines of business when prior authorized:

Code	Description	Effective
	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-	4/1/2020
0169U	methyltransferase) (eg, drug metabolism) gene analysis, common variants	
	Neurology (autism spectrum disorder [ASD]), RNA, next-generation	4/1/2020
	sequencing, saliva, algorithmic analysis, and results reported as predictive	
0170U	probability of ASD diagnosis	
	Targeted genomic sequence analysis panel, acute myeloid leukemia,	4/1/2020
	myelodysplastic syndrome, and myeloproliferative neoplasms, DNA	
	analysis, 23 genes, interrogation for sequence variants, rearrangements and	
0171U	minimal residual disease, reported as presence/absence	

The following code is covered for My Care Family members when prior authorized; remains not covered for Commercial members:

Code	Description	Effective
Q4186	Epifix, per sq cm	4/1/2020

The following code is covered for My Care Family members no prior authorization is required; remains not covered for Commercial members:

Code	Description	Effective
T4538	Diaper service, reusable diaper, each diaper	4/1/2020

The following codes are covered but not separately reimbursable:

Code	Description	Effective
	Services performed by a physical therapist assistant in the home health	4/1/2020
	setting in the delivery of a safe and effective physical therapy maintenance	
G2168	program, each 15 minutes	
	Services performed by an occupational therapist assistant in the home	4/1/2020
	health setting in the delivery of a safe and effective physical therapy	
G2169	maintenance program, each 15 minutes	

The following services/devices are not covered per benefits for all lines of business:

Code	Description	Effective
N/A	Medi-Belt Insulin Pump Carrier	
N/A	iPads	
N/A	Breg Polar Care Cubes Code Therapy System	
N/A	Willow portable Breast Pumps	
N/A	Posey Bed	
N/A	Residential and commercial water softening, filtration and conditioning systems	
T1000	Private duty/independent nursing service(s), licensed, up to 15 minutes	6/1/2020
G1012	Clinical decision support mechanism agilemd, as defined by the medicare appropriate use criteria program	4/1/2020
G1013	Clinical decision support mechanism evidencecare imaging advisor, as defined by the medicare appropriate use criteria program	4/1/2020
G1014	Clinical decision support mechanism inveniqa semantic answers in medicine, as defined by the medicare appropriate use criteria program	4/1/2020
G1015	Clinical decision support mechanism reliant medical group, as defined by the medicare appropriate use criteria program	4/1/2020
G1016	Clinical decision support mechanism speed of care, as defined by the medicare appropriate use criteria program	4/1/2020
G1017	Clinical decision support mechanism healthhelp, as defined by the medicare appropriate use criteria program	4/1/2020
G1018	Clinical decision support mechanism infinx, as defined by the medicare appropriate use criteria program	4/1/2020
G1019	Clinical decision support mechanism logicnets, as defined by the medicare appropriate use criteria program	4/1/2020

Code	Description	Effective
N/A	Bee Venom Therapy	
N/A	AxioBionics Wearable Therapy NMES	
N/A	NeuroMD Corrective Therapy Device	
C9056	Injection, givosiran, 0.5 mg	4/1/2020
	Oncology (colorectal) screening, biochemical enzyme-linked	4/1/2020
	immunosorbent assay (ELISA) of 3 plasma or serum proteins	
	(teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1],	
	carcinoembryonic antigen [CEA], extracellular matrix protein [(ECM)],	
	with demographic data (age, gender, CRC-screening compliance) using a	
	proprietary algorithm and reported as likelihood of CRC or advanced	
0163U	adenomas	
	Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-	4/1/2020
	CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated	
0164U	or not elevated qualitative results	
	Peanut allergen-specific IgE and quantitative assessment of 64 epitopes	4/1/2020
	using enzyme-linked immunosorbent assay (ELISA), blood, individual	
0165U	epitope results and interpretation	
	Liver disease, 10 biochemical assays (?2-macroglobulin, haptoglobin,	4/1/2020
	apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol,	
	fasting glucose) and biometric and demographic data, utilizing serum,	
	algorithm reported as scores for fibrosis, necroinflammatory activity, and	
0166U	steatosis with a summary interpretation	
	Gonadotropin, chorionic (hCG), immunoassay with direct optical	4/1/2020
0167U	observation, blood	
	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of	4/1/2020
	selected regions using maternal plasma without fetal fraction cutoff,	
0168U	algorithm reported as a risk score for each trisomy	

The following services/devices are not covered as they are considered experimental/investigational:

The following drugs are covered under the medical benefit for all lines of business no prior authorization is required:

Code	Description	Effective
C9054	Injection, lefamulin (Xenleta), 1mg	3/26/2020
J0121	Injection, omadacycline, 1 mg (Nuzyra)	3/26/2020
Q5116	Injection, trastuzumab-qyyp, biosimilar, (Trazimera), 10 mg	3/26/2020

The following drugs are covered under the medical benefit for all lines of business when prior authorized:

Code	Description	Effective
C9053	Injection, crizanlizumab-tmca, 1 mg (Adakveo)	3/26/2020
J0179	Injection, brolucizumab-dbll, 1 mg (Beovu)	3/26/2020
J3398	Injection, voretigene neparvovec-rzyl, 1 billion vector genomes (Luxturna)	1/1/2019
	(luspatercept-aamt) subcutaneous injection (Reblozyl) represented by	3/26/2020
N/A	J3590 Unclassified biologics	
	Rituximab-pvvr injection, for intravenous use (Ruxience) represented by	2/27/2020
N/A	unlisted code J3490	
	Antihemophilic factor recomb, glycopegylated-exe (Esperoct) represented	2/27/2020
N/A	by unlisted code J3590	
	(Meloxicam) Injection 30 mg/ML (ANJESO) represented by J3490	5/7/2020
N/A	Unclassified drugs	
		5/7/2020
Q5113	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg	

NEW BENEFIT: Preventive Pre-Exposure Prophylaxis (PrEP) for HIV

Effective 6/1/2020, AllWays Health Partners covers preventive services associated with PrEP for HIV. This coverage includes testing to determine if a member is eligible for treatment including office visits, laboratory testing and preventive medical counseling covered under the medical benefit. Not all self-insured accounts may have accepted this change. Preventive service providers should continue to confirm member eligibility and benefits as they normally do.

For billing information please see the AllWays Health Partners <u>Preventive Services Provider</u> <u>Payment Guideline</u>.